How Mannkind's Afrezza Is Revolutionizing Treatment for Diabetics

Alexander Moschina
by Alexander Moschina, Managing Editor, Investment U

How Mannkind's Afrezza Is Revolutionizing Treatment for Diabetics

by Alexander Moschina, Investment U Research

Friday, July 30, 2010

The average person gets a vaccination shot once every 10 years or so to prevent tetanus. Sure, we may pay for the occasional flu shot or some other kind of vaccination, but by and large, we avoid shots - quite ironically - like the plague.

Aside from the obvious health benefits, shots are only administered when absolutely necessary. And for most of us, that means rarely.

But for those who suffer from diabetes, the need for daily insulin injections can lead to unsightly bruises, scarring and grape-sized fatty deposits around injection areas. The ritual itself can be painful, too.

But despite the complications or the pain and inconvenience that come with injections, it remains the most common form of insulin delivery. But that may not be the case for much longer...

Mannkind "Just Says No" To Needles

MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company that develops and commercializes drugs that help fight life-threatening diseases, has created an insulin therapy that mimics the natural releases of insulin more effectively than current industry standards.

It also helps control glucose levels and fights the onset of hypoglycemia. But most importantly, the product is inhalable. As in no needle required.

The company, founded in 1991 and headquartered in Valencia, California, saw a 7.6% jolt on July 20 after the announcement that it had resubmitted a New Drug Application for inhalable insulin called Afrezza.

This came just three weeks after the FDA asked MannKind to provide more clinical data to support its product, as well as information about the specialized inhaler that is used to deliver it.

The speedy resubmission certainly inspired confidence in analysts and investors. And it's easy to see why. Simply put, Afrezza is going to change the way insulin is delivered for the 23.6 million Americans currently living with the disease and the 1.6 million new cases that are diagnosed each year.

Insulin Injections Could Be Made Obsolete

Currently, the injection ritual of most insulin users goes something like this:

  • After ensuring that the insulin is properly mixed, a rubber stopper on the top of the bottle is sterilized and the half-inch needle of a fresh syringe is pushed through to the insulin.

  • The plunger is pulled back, bringing insulin into the syringe.

  • The person then swabs the injection site on the body with alcohol. The skin around the area is pinched, the needle is aimed, and...

You get the idea.

With Afrezza, this time-consuming and unpleasant process could be made obsolete. An inhaler that is smaller than the palm of your hand delivers the powdered insulin therapy. It takes single-use cartridges that are simply activated by inhaling.

Afrezza: The Alternative to Daily Diabetic Injections

This revolutionary treatment will make life better for millions of afflicted individuals, many of whom may be under-medicating or skipping their daily injections because of the pain. Afrezza won't just be an alternative option...

It will be the standard.

The FDA announced that it will make its decision by December 29. Expect MannKind's stock to yo-yo plenty in the meantime, but once the drug is approved, the company is going to skyrocket.

Good investing,

Alexander Moschina

comments powered by Disqus